Innate Pharma announces updated results that support advancement of IPH4102 in refractory Sézary syndrome at the American Society of Hematology (ASH) 2018 annual meeting
December 3, 2018Differentiating profile of IPH4102 confirmed: high and durable response, favorable safety profile with long-term follow-up and substantial improvement in quality of life Innate Pharma expects to...Innate Pharma announces publication of monalizumab research in the prestigious “Cell” journal widening the horizon of immune checkpoint inhibitors
November 30, 2018Monalizumab is a first-in-class broad-spectrum immune checkpoint inhibitor with a dual effect on both Natural Killer (NK) cells and T lymphocytes Monalizumab showed promising preclinical and clinical...Innate Pharma appoints experts to new Strategic Advisory Board
November 20, 2018Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced the appointment of six leading experts to its newly formed Strategic Advisory Board (SAB). The SAB will work with...Third quarter 2018 report
November 15, 2018Acceleration of becoming a fully integrated oncology-focused biotech company through a recent landmark deal with AstraZeneca Expansion of oncology development collaboration with AstraZeneca validates...SITC 2018: further analyses of the Phase II study of the combination of monalizumab and cetuximab in head and neck patients show encouraging survival data in both subgroups of IO-naïve and IO-pretreated SCCHN patients
November 12, 2018These data support the advancement of the clinical program, starting with the enrollment of an additional cohort of patients who received both prior platinum-based chemotherapy and PD-1/L1 inhibitors...Number of shares and voting rights of Innate Pharma as at November 1, 2018
November 8, 2018Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...
